A Federal Framework of Regulation for Medical Cannabis Use

While a patchwork of state cannabis laws exists, the lack of a unified, federal framework regulating medical cannabis places patients at risk, and undermines the relationships that doctors must maintain to ensure an effective and safe treatment paradigm. 

Such a framework is both overdue and sorely needed for safe, optimized care of patients across the country. 

ACS Comment to DEA Rescheduling Rule

ACS welcomes the Drug Enforcement Administration’s (DEA) proposal to reschedule marijuana to Schedule III.

ACS Expectations of CME Requirements for Cannabis Specialists

Cannabis Specialists (MD, DO, NP, or PA if authorized by each state program) must keep up to date on the emerging data in the field.

ACS Guidance for Dispensaries

The ACS believes that cannabis dispensaries play a vital role in providing care and products to patients.

Why A Medical Cannabis System Is More Important Than Ever

Now that recreational cannabis is rolling out in Massachusetts, why do we need a medical cannabis system anymore?

ACS Guidance on Driving as a Medical Cannabis Patient 

Many medications, like benzodiazepines, opioids, and antibiotics can lead to impairment.

ACS Response to Congressional RFI on Regulation of CBD and Derivatives 

Recently ACS was asked to provide a response to the request for information from Congress with regard to regulation of CBD and derivatives. 

ACS and ASA Comments on Senator Schumer’s Cannabis Opportunity and Administration Act

The below signed stakeholders are collectively parties that have an interest in or work with medical cannabis. 

ACS and MSNJ Letter to Attorney General Merrick Garland

Subsequent to the letter sent to you requesting that you exercise your authority under the Controlled Substances Act of 1970 (CSA), we write to support the request and to support your pragmatic efforts to do so.

ACS Letter To ONDCP Director Rahul Gupta

Congratulations on the confirmation as Director of the Office of National Drug Control Policy.

ACS Takes Issue with Wall Street Journal Advertisement

We write to you to express a concern over a recent ½ page advertisement in the Journal.

ACS Guidance to CDC on Pain Management

The Association of Cannabis Specialists would like to offer the following comments on the topic of acute and chronic pain management, per the CDC’s request.

ACS – MCRAA Joint Comments on FDA Proposed Research Guidelines

The MCRAA appreciates the opportunity to provide comments in response to the US Food and Drug Administration (FDA)’s Cannabis and Cannabis-Derived Compounds: Quality Considerations for Clinical Research Draft Guidance for Industry.

ACS Joint Amicus Brief to Supreme Court of Pennsylvania

The amici submitting this brief are concerned by the 52nd Judicial District's ("the District") probation supervision policy prohibiting medical marijuana use which is otherwise permitted by Pennsylvania law.

ACS Response to Oil (Vape) Pen Ban

The currently posed question of when or whether the embargoed oil cartridges can be released for sale has at least two separate issues embedded.

ACS Response to JAMA article entitled Most Doctors Know Nothing About Cannabis

In an editorial in JAMA, Dr. Nathaniel Morris laments that even in California, no medical education on cannabis was provided to him during medical school or residency.

ACS Guidance to Massachusetts on Veteran Care

Despite vocal advocacy by a few veterans, this bill is not in the interests of veterans or other patients.

ACS Guidance to Hawai'i on Anxiety Treatment

I write to you to support the petitions before you to include anxiety, depression, and insomnia as qualifying conditions for medical cannabis treatment in Hawai’i.